How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. Moss evaluates a case that requires CAR-T cell therapy and discusses practical issues hematologists should be aware of during introduction of this treatment.
Dr. Jason Gotlib gives a warm welcome to Editor-in-Chief Designee Dr. Laura Michaelis whose term begins in 2018. They discuss her vision for the publication.
September/October 2017 Volume 14, Issue 5
View all Features articles
View all Diffusion articles
Dr. Kenneth Anderson discusses ASH's role in health care reform.
View all president's column articles
View all Ask the Hematologist articles
View all Op-Ed articles
View all Mini Review articles
ASH submitted comments to the NIH on hematology-related pediatric research that should be included in the NIH's All of Us research program.
After spending months crafting legislation to repeal and
replace the Affordable Care Act (ACA), in late July, the U.S. Senate had its
chance to vote on and pass repeal legislation.
The National Center for Advancing Translational Sciences (NCATS) released a request for information soliciting input on the use of viral vectors as platforms for therapeutic gene delivery to specific organs or cell types, and how such platforms might be developed most efficiently in clinical trials for the treatment of multiple diseases.
On July 13, 2017, the U.S. Senate released an updated
version of the Better Care Reconciliation Act (BCRA), legislation to repeal
large provisions of the Affordable Care Act (ACA).
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology